Article
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
Oncogene - 8 Jul 2004
Berthou Sylvie, Aebersold Daniel M, Schmidt Laura S, Stroka Deborah, Heigl Christine, Streit Bruno, Stalder Denise, Gruber Guenther, Liang Congxin, Howlett Anthony R, Candinas Daniel, Greiner Richard H, Lipson Kenneth E, Zimmer Yitzhak
Abstract excerpt
Point mutations constitute a major mode of oncogenic activation of the Met receptor tyrosine kinase. Met is aberrantly activated in many types of human malignancies and its deregulated activity is correlated with aggressive tumor traits such as abnormal proliferation and survival, leading to tumor growth, local invasion and metastasis. Here we report that the Met kinase inhibitor SU11274 differentially affects...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.